Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

90.79
-2.7400-2.93%
Post-market: 90.790.00000.00%16:20 EDT
Volume:514.11K
Turnover:46.98M
Market Cap:4.43B
PE:-21.00
High:93.47
Open:93.47
Low:90.75
Close:93.53
52wk High:151.02
52wk Low:44.42
Shares:48.77M
Float Shares:29.72M
Volume Ratio:0.67
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3223
EPS(LYR):-3.7900
ROE:-1433.70%
ROA:-25.78%
PB:-346.41
PE(LYR):-23.96

Loading ...

Celcuity to report Q1 results, host webcast and conference call after market close

Reuters
·
May 07

Is It Too Late To Consider Celcuity (CELC) After Its Recent Share Price Surge?

Simply Wall St.
·
May 07

Celcuity director David Dalvey reports disposal of 25,000 shares worth $3.52 million

Reuters
·
May 07

Celcuity director Richard E. Buller disposes of 9,000 common shares for $1,260,514

Reuters
·
May 07

Top Midday Gainers

MT Newswires Live
·
May 05

Celcuity rises 17.1%

TIPRANKS
·
May 04

Celcuity price target raised to $189 from $141 at Craig-Hallum

TIPRANKS
·
May 04

HC Wainwright Upgrades Celcuity to Buy From Neutral, Adjusts Price Target to $165 From $94

MT Newswires Live
·
May 04

Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results

Dow Jones
·
May 04

S&P 500 Futures Fall In Premarket Trading; Victory Capital, Black Hills Lag

Dow Jones
·
May 04

Guggenheim Keeps Their Buy Rating on Celcuity (CELC)

TIPRANKS
·
May 04

Celcuity Inc : H.c. Wainwright Raises to Buy From Neutral; Raises Target Price to $165 From $94

THOMSON REUTERS
·
May 04

Celcuity upgraded to Buy from Neutral at H.C. Wainwright

TIPRANKS
·
May 04

Celcuity price target raised to $160 from $150 at Citizens

TIPRANKS
·
May 04

Celcuity Is Maintained at Buy by Needham

Dow Jones
·
May 04

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Boston Scientific (BSX)

TIPRANKS
·
May 04

Celcuity Inc : Needham Raises Target Price to $155 From $122

THOMSON REUTERS
·
May 04

U.S. RESEARCH ROUNDUP- Alphabet, Colgate-Palmolive, Welltower

Reuters
·
May 04

Celcuity’s Phase 3 VIKTORIA-1 trial achieves primary endpoint

TIPRANKS
·
May 02

Celcuity says Phase 3 VIKTORIA-1 meets primary endpoint in PIK3CA-mutant breast cancer

Reuters
·
May 02